

Jan Delaval please

Access DB#

114138

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: *Sakcha Wozz* Examiner #: *7414* Date: *2/10/04*
Art Unit: *1616* Phone Number *308622* Serial Number: *10/035,251*
Mail Box and Bldg/Room Location: *4C 70* Results Format Preferred (circle) *PAPER* DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: *Vit. D Derivative for treating agent*
Inventors (please provide full names): *Kazuya Takenouchi*

Earliest Priority Filing Date: *4/23/2001*, Div. of *09/830,167*

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

*Please search for Vit D Compds
of for (1) in cl. 1.*

Please see attached sheets

Thank you.

RECEIVED
FEB 11 2004
STIC

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <i>6</i>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/> _____
Searcher Phone #: <i>71504</i>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <input checked="" type="checkbox"/> _____	Questel/Orbit _____
Date Searcher Picked Up: <i>2/15</i>	Bibliographic _____	Dr. Link _____
Date Completed: <i>2/13</i>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <i>20</i>	Patent Family _____	WWW/Internet _____
Online Time: <i>+ 40</i>	Other _____	Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 11:55:03 ON 13 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2

DICTIONARY FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que 113

L2 STR



VAR G2=OH/35/40/45/47/51/60

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 29

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 5 12


NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L3 SCR 1841

L8 1808 SEA FILE=REGISTRY CSS FUL L2 AND L3

L11 STR



REP G1=(0-2) CH2

VAR G2=C/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY SAT AT 1

GGCAT IS PCY SAT AT 4

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E6 C AT 1

ECOUNT IS E9 C AT 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L13 116 SEA FILE=REGISTRY SUB=L8 SSS FUL L11

100.0% PROCESSED 1808 ITERATIONS

116 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'REGISTRY' ENTERED AT 11:22:54 ON 13 FEB 2004)

DEL HIS

ACT QAZI270/A

L1 STR

L2 STR L1

L3 SCR 1841

L4 50 S L2 AND L3 CSS SAM

FILE 'HCAPLUS' ENTERED AT 11:29:51 ON 13 FEB 2004

L5 1 S (US20020132799 OR US6531460)/PN OR (WO99-JP5826 OR JP98-36520
SEL RN

FILE 'REGISTRY' ENTERED AT 11:31:07 ON 13 FEB 2004

L6 182 S E1-E182

L7 59 S L6 AND C5-C6/ES AND C6/ES AND NR>=4

L8 1808 S L2 AND L3 CSS FUL

SAV L8 QAZI035/A

L9 58 S L6 AND L8

L10 1 S L7 NOT L9

L11 STR

L12 7 S L11 SAM SUB=L8
L13 116 S L11 FUL SUB=L8
SAV L13 QAZI035A/A
L14 38 S L6 AND L13
L15 20 S L9 NOT L14
L16 78 S L13 NOT L14
L17 7 S L16 AND C28H40O3
SEL RN 1 2
L18 2 S E183-E184
SAV L14 QAZI035B/A
SAV L18 QAZI035C/A

FILE 'HCAOLD' ENTERED AT 11:54:06 ON 13 FEB 2004

L19 0 S L14
L20 0 S L18

FILE 'HCAPLUS' ENTERED AT 11:54:08 ON 13 FEB 2004

L21 1 S L14
L22 3 S L18
L23 1 S L21, L22 AND L5
L24 3 S L22 NOT L23

FILE 'USPATFULL, USPAT2' ENTERED AT 11:54:45 ON 13 FEB 2004

L25 7 S L14
L26 1 S L18
L27 8 S L25, L26


FILE 'REGISTRY' ENTERED AT 11:55:03 ON 13 FEB 2004

=> d ide can tot l14

L14 ANSWER 1 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266686-90-2 REGISTRY
CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-
[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-
methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-
yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C43 H74 O5 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.

Applicants'
Compounds



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 2 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

266686-88-8 REGISTRY

6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-
 (3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-
 methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-
 yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C43 H74 O5 Si2

SR	CA
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 3 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266686-86-6 REGISTRY
CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C43 H72 O5 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 4 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-67-6 REGISTRY
CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 5 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-66-5 REGISTRY
CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 6 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-65-4 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 7 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-64-3 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 8 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **266344-63-2** REGISTRY
 CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C42 H74 O5 Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 9 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
 RN **266344-62-1** REGISTRY
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C41 H70 O5 Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 10 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-61-0 REGISTRY

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C27 H38 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 11 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-60-9 REGISTRY

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C27 H38 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 12 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-58-5 REGISTRY

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C27 H38 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 13 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266344-54-1** REGISTRY

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 14 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-40-5 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 15 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-39-2 REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 16 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266344-38-1 REGISTRY
CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 17 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266344-35-8** REGISTRY

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 18 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266344-32-5** REGISTRY

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C40 H68 O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 19 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266344-29-0** REGISTRY

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethyldiene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C40 H68 O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 20 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-26-7 REGISTRY

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)-(9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C27 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 21 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN **266344-23-4** REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H40 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 22 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN **266344-20-1** REGISTRY
CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C39 H68 O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 23 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-17-6 REGISTRY

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C26 H39 N O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 24 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-14-3 REGISTRY

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C38 H67 N O5 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 25 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266344-11-0 REGISTRY

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C26 H37 N O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 26 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266344-08-5** REGISTRY

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C38 H65 N O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 27 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN **266344-05-2** REGISTRY
CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C38 H65 N O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 28 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN **266344-00-7** REGISTRY
CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H39 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 29 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266343-93-5 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 30 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266343-91-3 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 31 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266343-88-8 REGISTRY
CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 32 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN
RN 266343-85-5 REGISTRY
CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H39 F O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 132:322032

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 35 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN **266343-78-6** REGISTRY

CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C40 H68 O3 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 36 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266343-75-3 REGISTRY

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C27 H41 N O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 37 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266343-74-2 REGISTRY

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C39 H69 N O4 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

L14 ANSWER 38 OF 38 REGISTRY COPYRIGHT 2004 ACS on STN

RN 266343-73-1 REGISTRY

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C39 H69 N O4 Si2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:322032

=> d ide can tot 118

L18 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 593245-63-7 REGISTRY
CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H40 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 2: 139:240380

RN 401593-62-2 REGISTRY

OTHER NAMES:


FS STEREOSEARCH

MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 2: 139:240380

REFERENCE 3: 136:194682

```
=> fil hcaplus
```

FILE 'HCAPLUS' ENTERED AT 11:55:34 ON 13 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Feb 2004 VOL 140 ISS 7
FILE LAST UPDATED: 11 Feb 2004 (20040211/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 124

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:796311 HCAPLUS
DN 139:317460
ED Entered STN: 10 Oct 2003
TI Agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone
IN Ishizuka, Seiichi; Takenouchi, Kazuya; Imaizumi, Atsushi; Oue, Yasuhiro; Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, G. David
PA Teijin Limited, Japan
SO U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 79,890.
CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-59

ICS A61K031-366

NCL 514167000; 514460000

CC 1-10 (Pharmacology)

Section cross-reference(s): 3

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003191094	A1	20031009	US 2003-369752	20030221
PRAI	US 2002-79890	A2	20020222		
OS	MARPAT 139:317460				

AB To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor. A method for screening a compound for treatment of Paget's disease of bone comprises detecting expression of TAFII-17, TAFII-135, and DRIP-205 transcription factors in mononuclear cells from bone marrow collected from patients with the disease. Compound (23S)-25-dehydro-1 α -hydroxyvitamin D3-26,23-lactone suppressed expression of the gene for transcription factor TAFII-17 in bone marrow mononuclear cells from patients with Paget's disease of bone. The compound also suppressed osteoclast formation.

ST Paget bone disease inhibitor transcription factor steroid hormone receptor; drug screening Paget disease transcription factor expression

IT Transcription factors

RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(DRIP-205; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Bone, disease

(Paget's; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Transcription factors

RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(TAFII-135; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Transcription factors

RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(TAFII-17; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Drug screening

Human

Protein sequences

(agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Retinoid X receptors

Steroid receptors

Vitamin D receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Bone marrow

(drug screening with mononuclear cells from; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Gene, animal

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(expression for TAFII-17, TAFII-135, or DRIP-205 in drug screening; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT RNA

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(extraction and anal. from bone marrow mononuclear cells; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Mononuclear cell (leukocyte)

(from bone marrow in drug screening; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Nucleic acid amplification (method)

(in drug screening; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT cDNA

RL: AMX (Analytical matrix); FMU (Formation, unclassified); ANST (Analytical study); FORM (Formation, nonpreparative)
(in drug screening; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interacting with steroid hormone receptor; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT Osteoclast

(suppression of formation of; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 593245-62-6
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 364331-02-2 459844-32-7 593245-83-1 593245-84-2 593245-85-3
 593245-86-4 593245-87-5 593245-88-6 593245-89-7 593245-90-0
 593245-91-1 609766-13-4 609858-58-4
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 266343-35-5 401593-62-2 593245-63-7 593245-64-8
 593245-65-9 593245-66-0 593245-67-1 593245-68-2 593245-69-3
 593245-70-6 593245-71-7 593245-72-8 593245-73-9 593245-74-0
 593245-75-1 593245-76-2 593245-77-3 593245-78-4 593245-79-5
 593245-80-8 593245-81-9 593245-82-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 612549-25-4, Transcription factor TAFII-17 (human)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 612549-24-3
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (antisense PCR primer for human transcription factor TAFII-17; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)


IT 32222-06-3, 1 α ,25-Dihydroxyvitamin D3
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (induction of TAFII-17 in bone marrow cells of patients with Paget's disease; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 612549-23-2
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (sense PCR primer for human transcription factor TAFII-17; agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

IT 401593-62-2 593245-63-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)


RN 401593-62-2 HCAPLUS
 CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 593245-63-7 HCAPLUS
CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:717265 HCAPLUS
DN 139:240380
ED Entered STN: 12 Sep 2003
TI Compound inhibiting expression of general transcription factor of steroid hormone receptor for treatment of Paget's disease of bone
IN Ishizuka, Seiichi; Takenouchi, Kazuya; Imaizumi, Atsushi; Oue, Yasuhiro; Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, David G.
PA Teijin Limited, Japan
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C12Q001-68

ICS A61K031-592; A61K031-593; A61K038-08; A61P019-08
 CC 1-10 (Pharmacology)

Section cross-reference(s): 2

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1342796	A2	20030910	EP 2003-251072	20030221
	EP 1342796	A3	20040102		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI US 2002-79890 A 20020222

OS MARPAT 139:240380

AB To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor. Expression of the gene for the transcription factor TAFII-17 in bone marrow mononuclear cells from patients with Paget's disease was suppressed with (23S)-25-dehydro-1-hydroxyvitamin D3-26,23-lactone (I). I suppressed the gene expression even in the presence of 1 α ,25-dihydroxyvitamin D3 which induces its expression. The TAFII-17 gene was not expressed in bone marrow cells from normal adults. I also suppressed osteoclast formation induced by 1 α ,25-dihydroxyvitamin D3.

ST Paget bone disease inhibition steroid receptor transcription factor;
 transcription factor TAFII17 vitamin D3 receptor Paget bone;
 hydroxyvitamin D3 compd suppression osteoclast formation Paget bone

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DRIP-205 (Vitamin D receptor-interacting proteins-205); hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)

IT Bone, disease

(Paget's; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TAFII-135 (TATA box-binding protein-associated factor II-135); hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)

IT Transcription factors

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 BIOL (Biological study); PREP (Preparation)
 (TAFII-17 (TATA box-binding protein-associated factor II-17); hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)

IT Bone marrow

(TAFII-17 or TAFII-135 or DRIP-205 transcription factor expression in; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)

IT Mononuclear cell (leukocyte)

(TAFII-17 or TAFII-135 or DRIP-205 transcription factors expression in; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)


IT RNA

RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
 (for TAFII-17 or TAFII-135 or DRIP-205 transcription factors, detection of, in drug screening; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for

- treatment of Paget's bone disease)
- IT Gene, animal
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
 (for TAFII-17 or TAFII-135 or DRIP-205 transcription factors; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT DNA sequences
 Drug screening
 Human
 Protein sequences
 (hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT Nucleic acid amplification (method)
 (in drug screening; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT Retinoid X receptors
 Steroid receptors
 Vitamin D receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibition of transcription factor of; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (of steroid hormone receptor, inhibition of; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT Osteoclast
 (suppression of formation of; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT Genetic element
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (vitamin D-responsive element; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 32222-06-3, 1 α ,25-Dihydroxyvitamin D3
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Paget's disease-specific vitamin D receptor-binding protein induced by; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 53112-53-1, 25-Hydroxyvitamin D3-24-hydroxylase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TAFII-17 gene and dihydroxyvitamin D3 induction of expression of; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 364331-02-2 459844-32-7 593245-83-1 593245-84-2 593245-85-3
 593245-86-4 593245-87-5 593245-88-6 593245-89-7 593245-90-0
 593245-91-1 593245-92-2 593289-82-8
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)


- IT 595610-80-3
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 266343-35-5 **401593-62-2** 593245-62-6 **593245-63-7**
 593245-64-8 593245-65-9 593245-66-0 593245-67-1 593245-68-2
 593245-69-3 593245-70-6 593245-71-7 593245-72-8 593245-73-9
 593245-74-0 593245-75-1 593245-76-2 593245-77-3 593245-78-4
 593245-79-5 593245-80-8 593245-81-9 593245-82-0
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 593289-84-0
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (nucleotide sequence of antisense PCR primer for TAFII-17 gene; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT 593289-83-9
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (nucleotide sequence of sense PCR primer for TAFII-17 gene; hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- IT **401593-62-2** **593245-63-7**
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydroxyvitamin D3 compds. inhibiting expression of general transcription factor of steroid hormone receptors for treatment of Paget's bone disease)
- RN 401593-62-2 HCAPLUS
- CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 593245-63-7 HCAPLUS
 CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:157566 HCAPLUS
 DN 136:194682
 ED Entered STN: 01 Mar 2002
 TI Use of vitamin D derivatives as bone resorption inhibitors
 IN Ishizuka, Seiichi; Takenouchi, Kazuya; Imaizumi, Atsushi; Oue, Yasuhiro;
 Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, G. David
 PA Teijin Limited, Japan; University of Texas, Health Science Center
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 2-10 (Mammalian Hormones)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002015894	A2	20020228	WO 2001-US22614	20010822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2002069003	A2	20020308	JP 2000-252177	20000823
AU 2001084657	A5	20020304	AU 2001-84657	20010822
EP 1311253	A2	20030521	EP 2001-963731	20010822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2003000820	A	20030422	NO 2003-820	20030221
US 2004019024	A1	20040129	US 2003-362565	20030804
PRAI JP 2000-252177	A	20000823		

WO 2001-US22614 W 20010822


OS MARPAT 136:194682

GI



- AB To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist. An example is given showing osteoclast formation suppression activity of I on the osteoclast formation induced by 1 α ,25-dihydroxyvitamin D3 from bone marrow cells of normal persons.
- ST vitamin D deriv bone resorption inhibitor
- IT Bone
(resorption, inhibitors; vitamin D derivs. as bone resorption inhibitors)
- IT Human
(vitamin D derivs. as bone resorption inhibitors)
- IT 1406-16-2D, Vitamin d, derivs. 173388-20-0 173388-21-1
401593-62-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)
- IT **401593-62-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)
- RN 401593-62-2 HCAPLUS
- CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=> fil uspatall

FILE 'USPATFULL' ENTERED AT 11:55:49 ON 13 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:55:49 ON 13 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> => d 127 bib abs hitstr tot

L27 ANSWER 1 OF 8 USPATFULL on STN

AN 2003:271486 USPATFULL

TI Treating agent for Paget's disease of bone

IN Ishizuka, Seiichi, Tokyo, JAPAN

Takenouchi, Kazuya, Tokyo, JAPAN

Imaizumi, Atsushi, Tokyo, JAPAN

Oue, Yasuhiro, Tokyo, JAPAN

Kurihara, Noriyoshi, Pittsburgh, PA, UNITED STATES

Reddy, Sakamuri V., Pittsburgh, PA, UNITED STATES

Roodman, G. David, Pittsburgh, PA, UNITED STATES

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2003191094 A1 20031009

AI US 2003-369752 A1 20030221 (10)

RLI Continuation-in-part of Ser. No. US 2002-79890, filed on 22 Feb 2002, PENDING

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20037

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 401593-62-2 593245-63-7

(agent inhibiting expression of general transcription factor with interactive relation to steroid hormone receptor as treating agent for Paget's disease of bone)

RN 401593-62-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 593245-63-7 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 2 OF 8 USPATFULL on STN

AN 2003:67760 USPATFULL

TI Vitamin D, derivatives and remedies for inflammatory respiratory diseases containing the same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA Teijin Limited, Osaka, JAPAN (non-U.S. corporation)

PI US 6531460 B1 20030311
 WO 2000024712 20000504
 AI US 2001-830167 20010423 (9)
 WO 1999-JP5826 19991022
 PRAI JP 1998-302321 19981023
 JP 1998-362827 19981221
 JP 1998-365207 19981222
 JP 1998-365208 19981222
 JP 1998-365209 19981222
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Qazi, Sabiha
 LREP Sughrue Mion, PLLC
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 3903
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds expressed by the following general formula (1), ##STR1##
 ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension; alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
 266343-91-3P 266343-93-5P 266344-00-7P
 266344-11-0P 266344-17-6P 266344-23-4P
 266344-26-7P 266344-35-8P 266344-38-1P
 266344-39-2P 266344-40-5P 266344-54-1P
 266344-58-5P 266344-60-9P 266344-61-0P
 266344-64-3P 266344-65-4P 266344-66-5P
 266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPTAFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-85-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPATFULL

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-60-9 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-61-0 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-64-3 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown:



RN 266344-65-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P 266344-62-1P
 266344-63-2P 266686-86-6P 266686-88-8P
 266686-90-2P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-74-2 USPATFULL


CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-78-6 USPATFULL
 CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-81-1 USPATFULL
 CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-82-2 USPTAFULL

CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-05-2 USPTAFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266344-08-5 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-14-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-20-1 USPTAFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-29-0 USPTAFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-32-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-62-1 USPATFULL


CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-63-2 USPATFULL


CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)



RN 266686-86-6 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-88-8 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-90-2 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 3 OF 8 USPATFULL on STN

AN 2002:243608 USPATFULL

TI Vitamin D3 dervative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002132799 A1 20020919

AI US 2002-35251 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222

DT Utility

FS APPLICATION

LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213

CLMN Number of Claims: 44

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
 266343-91-3P 266343-93-5P 266344-00-7P
 266344-11-0P 266344-17-6P 266344-23-4P
 266344-26-7P 266344-35-8P 266344-38-1P
 266344-39-2P 266344-40-5P 266344-54-1P
 266344-58-5P 266344-60-9P 266344-61-0P
 266344-64-3P 266344-65-4P 266344-66-5P
 266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-85-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-88-8 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-

2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPATFULL

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-60-9 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-61-0 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-64-3 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-65-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 266343-73-1P 266343-74-2P 266343-78-6P
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P 266344-62-1P
266344-63-2P 266686-86-6P 266686-88-8P
266686-90-2P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 USPATFULL


CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266343-74-2 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-78-6 USPATFULL
 CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-81-1 USPATFULL

CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-82-2 USPATFULL


CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-05-2 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266344-08-5 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-14-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-20-1 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266344-29-0 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-32-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-62-1 USPATFULL

CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 266344-63-2 USPATFULL


CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)



RN 266686-86-6 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-88-8 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-90-2 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 4 OF 8 USPATFULL on STN

AN 2002:192102 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002103173 A1 20020801
AI US 2002-35217 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE, MION, ZINN,, MACPEAK & SEAS, PLLC, Suite 800, 2100 Pennsylvania
Avenue, N.W., Washington, DC, 20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-85-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R, 3aS, 4E, 7aR)-4-[(2Z)-[(3S, 5R)-3, 5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R, 5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R, 3aS, 4E, 7aR)-4-[(2Z)-[(3S, 5R)-3, 5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S, 5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPATFULL

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-60-9 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


Double bond geometry as shown.



RN 266344-65-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPATFULL


CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPATFULL
 CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P 266344-62-1P
 266344-63-2P 266686-86-6P 266686-88-8P
 266686-90-2P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)


RN 266343-73-1 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-74-2 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R, 3aS, 4E, 7aR)-4-[(2Z)-[(3S, 5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-78-6 USPATFULL
 CN Cyclopentanone, 2-[2-[(1R, 3aS, 4E, 7aR)-4-[(2Z)-[(3S, 5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-81-1 USPATFULL
 CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266343-82-2 USPATFULL
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-05-2 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266344-08-5 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-14-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-20-1 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-62-1 USPATFULL

CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 266344-63-2 USPATFULL

CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)- (9CI) (CA INDEX NAME)




RN 266686-86-6 USPATFULL
 CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266686-88-8 USPATFULL
 CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266686-90-2 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 5 OF 8 USPATFULL on STN

AN 2002:186118 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002099039 A1 20020725
US 6689766 B2 20040210
AI US 2002-35211 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC,
20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-85-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPATFULL

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-60-9 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-61-0 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-64-3 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-65-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPATFULL


CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPATFULL
 CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P 266344-62-1P
 266344-63-2P 266686-86-6P 266686-88-8P
 266686-90-2P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 USPATFULL
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-74-2 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-78-6 USPATFULL

CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-81-1 USPATFULL

CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-82-2 USPATFULL

CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-05-2 USPATFULL

2-
CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]o
ctahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-08-5 USPATFULL

2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-14-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-20-1 USPATFULL


CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-62-1 USPATFULL
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-63-2 USPATFULL
 CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)




RN 266686-86-6 USPATFULL
 CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266686-88-8 USPATFULL
 CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266686-90-2 USPATFULL

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 6 OF 8 USPATFULL on STN

AN 2002:172352 USPATFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)
PI US 2002091109 A1 20020711
US 6548489 B2 20030415
AI US 2002-35219 A1 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC,
20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4194

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P


(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266343-85-5 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPATFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPATFULL

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPATFULL

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-60-9 USPATFULL

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.






RN 266344-65-4 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPATFULL

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 266343-73-1P 266343-74-2P 266343-78-6P
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P 266344-62-1P
266344-63-2P 266686-86-6P 266686-88-8P
266686-90-2P

```


(1) preparation of vitamin D3 derivs. as remedies for inflammatory respiratory
diseases and other diseases)

```

RN 266343-73-1 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-74-2 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-78-6 USPATFULL

CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-81-1 USPATFULL

CN Silane, [[[1R, 3S, 5Z]-4-methylene-5-[(2E)-[(1R, 3aS, 7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-82-2 USPATFULL

CN Cyclopentanone, 5-[2-[(1R, 3aS, 4E, 7aR)-4-[(2Z)-[(3S, 5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-05-2 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-08-5 USPATFULL

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-14-3 USPATFULL

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-20-1 USPATFULL

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-29-0 USPATFULL

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-32-5 USPATFULL


CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-62-1 USPATFULL
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 266344-63-2 USPATFULL
 CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)



RN 266686-86-6 USPTAFULL

CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-88-8 USPTAFULL


CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-90-2 USPATFULL
 CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L27 ANSWER 7 OF 8 USPAT2 on STN
 AN 2002:186118 USPAT2
 TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
 IN Takenouchi, Kazuya, Tokyo, JAPAN
 Gao, Qingzhi, Tokyo, JAPAN
 Manabe, Kenji, Tokyo, JAPAN
 Sogawa, Ryo, Tokyo, JAPAN
 Takano, Yasuhiro, Tokyo, JAPAN
 Ishizuka, Seiichi, Tokyo, JAPAN

PA Teijin Limited, Tokyo, JAPAN (non-U.S. corporation)
PI US 6689766 B2 20040210
AI US 2002-35211 20020104 (10)
RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Sughrue Mion, PLLC
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formula (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-85-5 USPAT2

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPAT2

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPAT2

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPAT2

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPAT2

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-60-9 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-61-0 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-64-3 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown..



RN 266344-65-4 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPAT2

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-67-6 USPAT2

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P 266344-62-1P
 266344-63-2P 266686-86-6P 266686-88-8P
 266686-90-2P


(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyloxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 266343-74-2 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-78-6 USPAT2

CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-81-1 USPAT2

CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-82-2 USPAT2

CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-05-2 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-08-5 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-14-3 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-20-1 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-29-0 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-32-5 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-62-1 USPAT2


CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-63-2 USPAT2


CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)



RN 266686-86-6 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-88-8 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-90-2 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L27 ANSWER 8 OF 8 USPAT2 on STN

AN 2002:172352 USPAT2

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA Teijin Limited, Osaka, JAPAN (non-U.S. corporation)
PI US 6548489 B2 20030415
AI US 2002-35219 20020104 (10)
RLI Division of Ser. No. US 830167
PRAI JP 1998-302321 19981023
JP 1998-362827 19981221
JP 1998-365207 19981222
JP 1998-365208 19981222
JP 1998-365209 19981222
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Sughrue Mion, PLLC
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1) to (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 266343-75-3P 266343-85-5P 266343-88-8P
266343-91-3P 266343-93-5P 266344-00-7P
266344-11-0P 266344-17-6P 266344-23-4P
266344-26-7P 266344-35-8P 266344-38-1P
266344-39-2P 266344-40-5P 266344-54-1P
266344-58-5P 266344-60-9P 266344-61-0P
266344-64-3P 266344-65-4P 266344-66-5P
266344-67-6P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-75-3 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-85-5 USPAT2

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-88-8 USPAT2

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-91-3 USPAT2

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-93-5 USPAT2

CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (2S,5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-00-7 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-1-methyl-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-11-0 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-17-6 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-23-4 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-26-7 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-35-8 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-38-1 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-39-2 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-40-5 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-54-1 USPAT2

CN 2-Cyclohexen-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-58-5 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-60-9 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-61-0 USPAT2

CN 2-Cyclopenten-1-one, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-64-3 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-65-4 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-66-5 USPAT2

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2S,3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-67-6 USPAT2

CN Cyclopentanone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 266343-73-1P 266343-74-2P 266343-78-6P
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P 266344-62-1P
266344-63-2P 266686-86-6P 266686-88-8P
266686-90-2P

(preparation of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-73-1 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-74-2 USPAT2

CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266343-78-6 USPAT2


CN Cyclopentanone, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-5-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266343-81-1 USPAT2
 CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266343-82-2 USPAT2
 CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-fluoro-2-methyl-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266344-05-2 USPAT2

CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2E)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-08-5 USPAT2


CN 2-Pyrrolidinone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (3E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 266344-14-3 USPAT2
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 266344-20-1 USPAT2
 CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 266344-29-0 USPAT2

CN Cyclopentanone, 4-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-32-5 USPAT2

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-62-1 USPAT2


CN Cyclopentanone, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-, (5E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 266344-63-2 USPAT2


CN Cyclopentanol, 5-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2,2-dimethoxy-1-methyl-, (5E)-(9CI) (CA INDEX NAME)



RN 266686-86-6 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-one, 2-[2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-88-8 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 266686-90-2 USPAT2

CN 6,10-Dioxaspiro[4.5]decan-1-ol, 2-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-8-methyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=>